Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.67)
# 790
Out of 5,090 analysts
81
Total ratings
58.21%
Success rate
27.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $14.60 | -17.81% | 5 | Sep 15, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $510 → $475 | $455.48 | +4.29% | 19 | Sep 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $458.12 | +12.43% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $6.50 | -69.23% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $56.88 | +74.05% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $35.00 | +28.57% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $7.59 | +58.10% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.42 | +106.61% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $41.67 | -16.01% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $577.30 | -37.64% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.10 | +81.82% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $54.55 | -30.34% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $36.38 | +119.90% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $12.93 | +39.21% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $5.24 | +377.10% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.43 | +444.32% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $44.90 | -46.55% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $18.55 | +61.73% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.42 | +126.24% | 1 | Feb 5, 2020 |
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $14.60
Upside: -17.81%
Vertex Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $510 → $475
Current: $455.48
Upside: +4.29%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $458.12
Upside: +12.43%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $6.50
Upside: -69.23%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $56.88
Upside: +74.05%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $35.00
Upside: +28.57%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $7.59
Upside: +58.10%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.42
Upside: +106.61%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $41.67
Upside: -16.01%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $577.30
Upside: -37.64%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.10
Upside: +81.82%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $54.55
Upside: -30.34%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $36.38
Upside: +119.90%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $12.93
Upside: +39.21%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $5.24
Upside: +377.10%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.43
Upside: +444.32%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $44.90
Upside: -46.55%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $18.55
Upside: +61.73%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.42
Upside: +126.24%